Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 286

Similar articles for PubMed (Select 23456621)

1.

Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.

Gao J, Tian Y, Li J, Sun N, Yuan J, Shen L.

Med Oncol. 2013 Jun;30(2):522. doi: 10.1007/s12032-013-0522-y. Epub 2013 Mar 2.

PMID:
23456621
2.

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

Li J, Gao J, Hong J, Shen L.

Future Oncol. 2012 May;8(5):617-24. doi: 10.2217/fon.12.29.

PMID:
22646775
3.

C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.

Gao J, Dang Y, Sun N, Li J, Shen L.

Med Oncol. 2012 Dec;29(5):3039-45. doi: 10.1007/s12032-012-0308-7. Epub 2012 Jul 20.

PMID:
22815156
4.

[Secondary mutation of c-kit/PDGFR╬▒ genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].

Hong JL, Li J, Li J, Shen L.

Zhonghua Bing Li Xue Za Zhi. 2012 Jun;41(6):386-90. doi: 10.3760/cma.j.issn.0529-5807.2012.06.006. Chinese.

PMID:
22932406
5.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

6.

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.

Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.

Anticancer Res. 2014 Sep;34(9):5029-36.

PMID:
25202087
7.

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK.

Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23.

PMID:
21104107
8.

[The importance of mutational status in prognosis and therapy of GIST].

Comandone A, Boglione A.

Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950. Italian.

PMID:
25621775
9.

The role of KIT in the management of patients with gastrointestinal stromal tumors.

Hornick JL, Fletcher CD.

Hum Pathol. 2007 May;38(5):679-87. Review.

PMID:
17437861
10.

[Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].

Liu X, Jiang WZ, Guan GX, Chen ZF, Chi P, Lu HS.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):221-5. Chinese.

PMID:
23536339
11.

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.

Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, Nakajima K, Hirota S; Japanese Study Group on GIST.

Int J Clin Oncol. 2009 Apr;14(2):143-9. doi: 10.1007/s10147-008-0822-y. Epub 2009 Apr 24.

PMID:
19390946
12.

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.

Med Oncol. 2008;25(2):207-13. doi: 10.1007/s12032-007-9014-2. Epub 2007 Oct 6.

PMID:
18488160
13.

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.

Wang CM, Huang K, Zhou Y, Du CY, Ye YW, Fu H, Zhou XY, Shi YQ.

J Cancer Res Clin Oncol. 2010 Jul;136(7):1065-71. doi: 10.1007/s00432-009-0753-7. Epub 2009 Dec 31.

PMID:
20043176
14.

[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

Italiano A, Bui B.

Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561. Review. French.

PMID:
18230576
15.

Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.

Chen YY, Yeh CN, Cheng CT, Chen TW, Rau KM, Jan YY, Chen MF.

World J Gastroenterol. 2011 Apr 28;17(16):2113-9. doi: 10.3748/wjg.v17.i16.2113.

16.

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.

Kikuchi H, Setoguchi T, Miyazaki S, Yamamoto M, Ohta M, Kamiya K, Sakaguchi T, Konno H.

Int J Clin Oncol. 2011 Dec;16(6):741-5. doi: 10.1007/s10147-011-0208-4. Epub 2011 Mar 12.

PMID:
21394667
17.

Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.

Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.

Acta Oncol. 2012 Apr;51(4):528-36. doi: 10.3109/0284186X.2011.636753. Epub 2011 Dec 7.

PMID:
22150077
18.

Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.

Liu NN, Ohkouchi M, Hashikura Y, Kajimoto N, Matsuda I, Isozaki K, Toh Y, Takahashi T, Nishida T, Hirota S.

Lab Invest. 2013 May;93(5):502-7. doi: 10.1038/labinvest.2013.43. Epub 2013 Mar 4.

19.

High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.

K├╝nstlinger H, Binot E, Merkelbach-Bruse S, Huss S, Wardelmann E, Buettner R, Schildhaus HU.

Hum Pathol. 2014 Mar;45(3):573-82. doi: 10.1016/j.humpath.2013.10.025. Epub 2013 Nov 4.

PMID:
24444465
20.

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.

Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2009 Nov 15;15(22):6862-70. doi: 10.1158/1078-0432.CCR-09-1315. Epub 2009 Oct 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk